Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.Greg Andrew Durm, Nasser H. Hanna, Ticiana Leal et al.|Journal of Clinical Oncology|2022Cited by 29
Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial.Melissa Yan, Nasser H. Hanna, Greg Andrew Durm et al.|Journal of Clinical Oncology|2020Cited by 12
Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081.Melissa Yan, Nasser H. Hanna, Greg Andrew Durm et al.|Journal of Clinical Oncology|2019Cited by 9
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081Greg Andrew Durm, Nasser H. Hanna, Hirva Mamdani et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 9
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)Laura Burns, Ümit Tapan, Chih–Yuan Hsu et al.|Lung Cancer|2023Cited by 1